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ScienceDirectInfection of the gastrointestinal tract is commonly linked to
pathological imbalances of the resident microbiota, termed
dysbiosis. In recent years, advanced high-throughput genomic
approaches have allowed us to examine the microbiota in an
unprecedented manner, revealing novel biological insights
about infection-associated dysbiosis at the community and
individual species levels. A dysbiotic microbiota is typically
reduced in taxonomic diversity and metabolic function, and can
harbour pathobionts that exacerbate intestinal inflammation or
manifest systemic disease. Dysbiosis can also promote
pathogen genome evolution, while allowing the pathogens to
persist at high density and transmit to new hosts. A deeper
understanding of bacterial pathogenicity in the context of the
intestinal microbiota should unveil new approaches for
developing diagnostics and therapies for enteropathogens.
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Introduction
The human intestinal microbiota is composed of 500–
1000 diverse species, which together contains approxi-
mately 150 times more unique genes than our genome [1].
Often viewed as a ‘‘digestive organ’’, the microbiota has
co-evolved with the host to form a complex mutualistic
relationship [2]: the gastrointestinal tract provides a nour-
ishing environment for its microbial community, while
the microbiota performs a wide range of essential
metabolic, developmental and immune functions. A
health-associated microbiota also represents the first
line of defence against invading pathogens or resident
Open access under CC BY license.www.sciencedirect.com opportunists, and can facilitate pathogen clearance from
the intestinal tract [3].
Over the past decade, the development of high-through-
put sequencing technologies and analysis tools has
enabled us to study the microbiota at an exceptional
depth and resolution. At the same time, there is an
increasing recognition that many pathogens such as
Clostridium difficile and enterococci harbour potent viru-
lence factors in their genomes, yet are commonly associ-
ated with asymptomatic carriage. Thus a pathogen’s
ability to manifest virulence versus commensalism cannot
be determined from the genome alone [4], and virulence
genes (e.g. those encoding bacterial toxins, antimicrobial
resistance, adhesion factors) may be essentially viewed as
colonization factors [4,5]. Disease manifestation often
depends not only on the dynamic between the pathogens
and host immunity, but also on the composition and
activity of the cohabiting microbiota. Recent studies
monitoring the microbiota in patients or murine models
of bacterial infection have indeed revealed new insights
about pathogen biology during dysbiosis, including host
colonization, disease, adaptation and transmission. Below,
we discuss emerging concepts on infection-associated
dysbiosis and their implications for host–microbe
interactions.
The intestinal microbiota during homeostasis
Without exposure to antibiotics or enteropathogens, a
healthy gastrointestinal tract is home to a dense and
diverse microbial community, known as the microbiota.
A typical intestinal microbiota is dominated by obligate
anaerobes belonging to the phyla Bacteroidetes, Firmi-
cutes and Actinobacteria, and facultative anaerobes of the
Proteobacteria phylum [6]. The microbiota assembly and
structure vary widely between different individuals and at
different anatomical sites along the length of the intes-
tinal tract [7]. Nevertheless, a health-associated micro-
biome (that is, the collective encoding potential of the
microbiota) is believed to be functionally conserved, and
contains a shared gene set necessary to perform important
biochemical reactions for host physiology [8]. These
functions include the degradation of xenobiotic sub-
stances, vitamin biosynthesis and fermentation of indi-
gestible polysaccharides into beneficial short-chain fatty
acids (SCFA). Colonization by microbes also promotes
our immune development, including the generation of
IgA-secreting plasma cells or regulatory T cells to estab-
lish intestinal homeostasis with the commensal micro-
biota [9]. Finally, a healthy gut ecosystem is essential for
colonization resistance [10,11,12], whereby both theCurrent Opinion in Microbiology 2014, 17:67–74
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Box 1 High-throughput methods to study host–microbiota
interactions (Figure 1)
16S rRNA gene sequencing:
The 16S ribosomal RNA gene is highly conserved among prokaryotic
species, and can be sequenced using various platforms (e.g. Roche
454 pyrosequencing, Illumina HiSeq/Miseq). By comparing to
publicly available rRNA gene databases (e.g. the Ribosomal
Database Project, SILVA, Greengenes), the 16S rRNA gene
sequence can be used as a surrogate marker to define the microbial
lineages present in a community. This allows researchers to analyse
the microbiota structure, including its taxonomic and phylogenetic
diversity. To classify 16S gene sequences into bacterial taxa (often
called Operational Taxonomic Units — OTUs), one commonly
assumes that those with 97% nucleotide identity can be assigned
to a single species. This assumption largely holds true except for a
few genera (e.g. Bacillus) in which distinct species only differ at a
few bases of their 16S sequence. Another limitation is that organisms
with significant polymorphism in the regions used for primer design,
such as Actinobacteria and Bifidobacteria spp., are poorly detected
with ‘‘universal’’ 16S gene primers [64].
Shotgun sequencing:
Bacterial DNA is broken into small fragments and sequenced.
Fragment sequences are assembled into contigs and aligned to
construct a complete genome. Traditionally, this method was used to
study organisms isolated and grown in pure cultures. Therefore,
genomic sequences were only obtained from cultured species and
represent merely a snapshot of one bacterial clone rather than of the
community as a whole. However, shotgun sequencing is being
increasingly applied directly to DNA obtained from mixed-community
samples (i.e. metagenomics). This technique allows us to under-
stand the community structure and also to build pathways describing
its function, especially when combined with mRNA or protein-based
quantification of the microbiota. Thus metagenomics is gaining
popularity as a method to study microbial ecosystems.
However, there are remaining challenges. Most environmental and
biological communities exhibit vast diversity and unevenness, with
large variations in the relative abundance of different members.
Therefore the genomes of rare species, especially those with the
potential to greatly influence its community or host (i.e. keystone
species), may be poorly detected or assembled even with deep
sequencing. Efforts are under way to improve assembly algorithms,
detection and normalization of previously under-studied phylotypes.
The current databases to classify microbial genes, enzymes and
pathways (e.g. COG, KEGG, CAZy) are also rapidly expanding,
which will enhance our ability to assign or predict the functional
capacity of the microbiome from shotgun sequences.
Culture-based methods:
Despite the advent of culture-independent methods to study microbial
communities, culture techniques still play an essential role in defining
host–microbe interactions. Although only <30% of members of the
human microbiota have been cultured to date, uncultured organisms
may not be in fact unculturable. Permissive growth conditions for these
organisms may be uncovered with improved, high-throughput cultur-
ing techniques [62]. Microbial culturing can allow us to study
biological aspects of the organism such as its growth, metabolism or
behaviour in a given host. In addition, the whole genomes of these
microbes may be sequenced to analyse for genetic traits (e.g.
symbiosis or virulence genes), or evidence of genomic evolution.
Finally, the functional output of the microbiota may be assessed by
sequencing the mRNA content (i.e. metatranscriptomics), quanti-
fying the proteome (i.e. metaproteomics) or the active metabolites
(i.e. metabolomics). These approaches are especially valuable for
studying the microbiota function during human clinical trials.
Current Opinion in Microbiology 2014, 17:67–74 microbial community and the basal immune responses
against resident commensals can together prevent access
of pathogens.
The intestinal microbiota during infections
The importance of the resident microbiota during intes-
tinal infections was highlighted by two seminal papers
utilizing murine infection models with the Gram-nega-
tive pathogens Salmonella enterica serovar Typhimurium
(or S. Typhimurium [13]) and Citrobacter rodentium
[14]. In both models, pathogen-induced inflammation
either led to or stabilized an imbalanced state of the
microbiota community structure and function, termed
intestinal dysbiosis. Advanced genomic methods have
since been applied to other infection models, including
Gram-positive and Gram-negative pathogens, to further
define dysbiosis at both the microbial community and
single species levels (Box 1 and Figure 1). Below, we
summarize some of the emerging concepts from these
studies.
Exploitation of dysbiosis by enteric pathogens
Diverse enteric pathogens often exploit dysbiosis,
whether precipitated by antibiotic use or host inflam-
mation, to outcompete resident commensals and gain
access to intestinal nutrients and niches. In mice, Salmo-
nella Typhimurium and Clostridium difficile can both
colonize the gut asymptomatically but only overgrow to
high density and induce pathology after antibiotic treat-
ment [13,15]. C. difficile is also the leading cause of
antibiotic-associated diarrhea in humans, whereby dis-
ease manifestation predominantly occurs following anti-
biotic disruption of the microbiota, or in patients with
inflammatory bowel disease [16]. When dysbiosis occurs,
pathogens can rapidly outcompete commensals due to a
greater resistance to host defences (e.g. antimicrobial and
phagocyte killing), and better utilization of the gut nutri-
ent environment [12,17]. For example, Salmonella’s com-
petitive advantage is partly conferred by the ability to
overcome host sequestration of iron [18] and to respire
anaerobically using reactive oxygen species derived from
the inflamed gut [19]. The metabolic environment during
dysbiosis is also high in the SCFAs acetate and formate,
which positively regulate the expression of Salmonella
pathogenicity island-1 [20,21]. In addition, antibiotic use
can lead to an increased availability of mucosal carbo-
hydrates that are normally consumed by commensal
Bacteroides, thus opening up new replicative niches for
pathogens such as Salmonella and C. difficile [22].
Dysbiosis is characterized by a simplified community
structure and function
Characterization of intestinal dysbiosis by different 16S
rRNA gene sequencing approaches has consistently
shown a reduction in taxonomic diversity and species
membership of the microbiota. This observation also
holds true across multiple human studies and animalwww.sciencedirect.com
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High-throughput genomic techniques commonly applied in microbiota research. (a) The functional state of the microbiota can be assessed directly by
measuring its transcriptome (i.e. RNA-sequencing or metatranscriptomics), proteome (i.e. metaproteomics) or metabolites (i.e. metabolomics). Such
approaches are still in their infancy but hold great promise for developing microbiota-based therapies and assessing human clinical studies. (b)
Microbiota composition and taxonomy can be determined through directed amplicon sequencing of the 16S rRNA genes or by extracting 16S rRNA
gene data from metagenomic datasets. Direct sequencing of the total DNA (i.e. shotgun metagenomics) also allows a measurement of the community
function by defining the proteins and pathways (e.g. KEGG, COG, RefSeq pathways) that could potentially be active in the community to infer the
overall functional capacity of the community. (c) Microbial species from the microbiota may be isolated and cultured by high-throughput techniques,
termed ‘‘culturomics’’, such as the use of barcoded plates with rich non-selective agar or liquid medium. The resulting microbes can then be whole-
genome sequenced to examine their genetic traits, or analysed biologically with in vitro or in vivo assays. A combination of these complementary
approaches will expand our understanding of the microbiota during health and disease and may ultimately yield microbiota-based therapeutics and
diagnostics.infection models, including S. Typhimurium, C. roden-
tium, C. difficile, and vancomycin-resistant enterococci
(VRE) [14,23–25,26,27,28]. The overall bacterial bio-
mass may decrease in some cases depending on the
inflammatory insult [14,29]. In addition, dysbiosis
generally leads to a depletion of obligate anaerobic bac-
teria such as Bacteroides and Ruminococcus spp., and con-
versely, a bloom in facultative anaerobes including the
family Enterobacteriaceae (e.g. E. coli, Klebsiella spp.,
Proteus spp.). This shift may partly be due to the ability
of Enterobacteriaceae species to respire using reactive
nitrogen species — a byproduct of host inflammation,
thereby outcompeting other commensals [30]. However,www.sciencedirect.com the complex mechanism underlying other population-
wide changes during dysbiosis (e.g. the bloom of
anaerobic Prevotella spp. driven by NLRP6 inflamma-
some deficiency [31]) remains unclear.
Among the functional consequences of a simplified
microbiota is a reduced metabolic capacity, often exem-
plified by a decline in SCFA production. This outcome
may be in part due to a reduction in anaerobic bacteria,
including dominant SCFA-producing genera such as Bac-
teroides, Clostridium, Bifidobacterium and Roseburia. SCFAs
are physiological byproducts of carbohydrate fermenta-
tion by the microbiota, and serve to salvage energy for theCurrent Opinion in Microbiology 2014, 17:67–74
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intestinal inflammation and oxidative stress [32]. Dysbio-
sis caused by broad-spectrum antibiotics (e.g. clindamy-
cin, cephalosporins), which can trigger opportunistic
infection by C. difficile and enterococci, is commonly
associated with low intestinal SCFA levels [23,33].
Furthermore, C. difficile infection may itself lead to
decreased amounts of faecal acetate and butyrate, both
in humans and equivalent murine models [25,33]. In the
streptomycin-induced model of S. Typhimurium infec-
tion, butyrate level also decreases in the large intestine,
which may promote bacterial invasion by stimulating
expression of the Salmonella pathogenicity island genes
[34]. As such, the microbiota’s declining metabolic
capacity may further impair host defence to pathogens
and promote the stability of a dysbiotic community.
The dysbiotic microbiota acts as a pathogenic
community
In S. Typhimurium infection, a microbiota with simpli-
fied structure (e.g. in mice treated with clinically relevant
doses of antibiotics) or increased Enterobacteriaceae
abundance may exacerbate disease outcome [35,36,
37]. The pathogenic role of a dysbiotic microbiota is also
shown in C. difficile-associated diarrhea, in which dysbiosis
caused by an epidemic C. difficile strain leads to relapsing
infection with more severe pathology [25]. Interestingly
in some infection models such as C. difficile [25] and
C. rodentium [14,28], microbiota analyses reveal that
the inciting pathogens often constitute only a minor
fraction of the overall microbial community. Together,
these findings suggest that low-abundance pathogens
could induce global changes to the microbiota structure
and function, in a manner that further destabilizes the
intestinal ecosystem. Such enteropathogens may be con-
sidered ‘keystone species’ [38], and likely influence the
microbial community through a combination of their
virulence expression, and of the host inflammatory and
metabolic responses.
A dysbiotic microbiota may also be enriched for patho-
bionts — resident species with virulence potential that
are normally kept at low levels. An overgrowth of com-
mensal Enterobacteriaceae (Klebsiella spp. and Proteus
spp.) or Helicobacter typhlonius has been shown to occur
during intestinal dysbiosis, and can directly trigger colitis
in mice [39]. Moreover, the depletion of anaerobic com-
mensals during dysbiosis can lead to intestinal overgrowth
of VRE, both in murine infection models or patients
undergoing antibiotic therapies [26,40]. This con-
sequently predisposes the host to invasive enterococcal
infections with life-threatening sequelae [26]. Similarly,
a multidrug-resistant E. coli pathobiont can expand in
the mouse intestine following antibiotic disruption of
the microbiota, causing bacteremia and sepsis [41].
Therefore during dysbiosis, the host may be increasingly
susceptible to both pathogens and pathobionts, and theCurrent Opinion in Microbiology 2014, 17:67–74 microbiota may be viewed collectively as a pathogenic
community.
An ecosystem for pathogen virulence expression and
genome evolution
The microbiota often influences pathogen virulence and
fitness upon passage through the gastrointestinal tract.
Signaling from commensal bacteria has been shown to
upregulate the virulence genes of enterohaemorrhagic E.
coli O157:H7 and facilitates its adaptation to the host [42].
Another attaching-effacing pathogen, C. rodentium, also
upregulates its virulence genes early during infection in a
microbiota-dependent manner [43]. In both C. roden-
tium and Vibrio cholerae-induced diarrhea, passage through
the gut allows the pathogens to efficiently colonize sub-
sequent hosts [44,45]. ‘‘Hyperinfectious’’ V. cholerae can
also persist in aquatic reservoirs — a phenotype associ-
ated with significant changes in the bacterial transcrip-
tome, including a repression of chemotactic factors and
upregulation of carbon metabolism [46].
In addition, pathogens may acquire virulence, fitness and
antimicrobial resistance genes from the gut community,
as they evolve under the selective pressures from host
immune defence, microbial competition or antibiotic use.
Transfer of antibiotic resistance genes by conjugative
transposons has long been shown to occur extensively
among pathogens and commensals, within the gut reser-
voirs of both humans and farm animals [47]. The hospital-
associated pathogen Enterococcus faecalis V583 can also
evolve in the intestinal tract by disseminating fluoroqui-
nolone resistance and fitness-enhancing bacteriophages
[48,49]. Using whole-genome sequencing and phyloge-
netics, He et al. recently demonstrated the rapid evol-
ution of an epidemic C. difficile strain (ribotype 027),
fuelled by antibiotic use and the transfer of mobile
genetic elements with other intestinal bacteria [50,51].
In addition, Stecher and colleagues combined 16S rRNA
gene and shotgun genome sequencing to show that
during enterobacterial blooms in the inflamed gut, patho-
genic Samonella and commensal E. coli can efficiently
exchange fitness genes via conjugative plasmids [52]. The
intestinal ecosystem represents a rich, dynamic reservoir
for pathogens to intermingle and exchange genetic
materials, especially during dysbiosis-induced bloom
[53]. Therefore limiting dysbiosis, especially in the hos-
pital setting, may have broad implications for the control
of emerging infectious diseases.
Enhanced disease persistence and host-to-host
transmission
Dysbiosis can promote pathogen transmission by increas-
ing the levels of shedding and prolonging the infectious
period. In both murine models of Salmonella and C.
difficile-induced disease, antibiotic disruption of the
microbiota leads to a remarkably high bacterial load
(108-109 CFU/g of faeces) [15,25,54]. This phenomenon,www.sciencedirect.com
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Features of intestinal dysbiosis during bacterial infections. (a) A healthy microbiota is typically diverse in structure and performs a wide range of
functions (e.g. xenobiotic metabolism, production of SCFAs), thereby maintaining a mutualistic metabolic relationship with the host. Colonization
resistance relies in part on the ability of the resident microbiota to outcompete pathogens for niches and nutrients. (b) During dysbiosis induced by
pathogen-mediated inflammation or antibiotic perturbation, the microbiota is reduced in both taxonomic diversity and function, and intestinal
colonization resistance is impaired. Diverse Gram-negative and Gram-positive pathogens can maintain dysbiosis by acting as keystone species to
modulate community-wide shifts in the microbiota, possibly by orchestrating the host inflammatory response. As a result, the microbial community
becomes more pathogenic, wherein pathogens and resident pathobionts may overgrow and even invade to cause systemic infection. Interactions with
the gut microbiota often also allow pathogens to express their virulence factors and evolve under selective pressures. Consequently, the pathogens’
increased fitness and over-colonization may exacerbate pathology and enhance host-to-host transmission.also known as the ‘‘supershedder’’ phenotype, allows
pathogens to transmit very effectively through direct
contact or environmental contamination. For example,
C. difficile supershedders can spread infection by releasing
millions of infectious spores, which persist in the environ-
ment for long periods of months or even years [25,55]. In a
clinical study involving VRE-infected patients, those
shedding high bacterial levels have also been shown to
contaminate their hospital surroundings [56]. In addition,
the clearance of many pathogens including Salmonella, C.
difficile and C. rodentium depends on the presence of a
healthy microbiota [25,36,43]. As such, intestinal dys-
biosis can also promote the spread of pathogens by allowing
them to establish persistent infection within the host.
Future perspectives on microbiota restoration
Each year, infectious diseases are increasingly difficult to
treat because of rising antimicrobial resistance and a
shortage in antibiotics discovery. Given the significant
impact of dysbiosis on pathogen-mediated disease and
transmission (Figure 2), the restitution of a healthy micro-
biota holds great promise as a therapy, at least for some
infections. There are compelling evidences to suggest
that administration of a diverse microbiota, or individualwww.sciencedirect.com probiotic species, can restrict or eliminate enteric patho-
gens. For example, microbiota transplantation may be
used in mice to prevent lethal disease caused by C.
rodentium and VRE [57,58]. Further, patients with
recurrent C. difficile infection, or murine supershedders,
can completely eliminate C. difficile after receiving a
healthy microbiota [25,59]. Interestingly, C. difficile sup-
pression may also be achieved by inoculating mice with
Lachnospiraceae species or a defined group of six
commensals (including the known probiotic Lactobacillus
reuteri and previously uncharacterized Bacteroidetes and
Anaerostipes spp.) [25,60]. This suggests that some
microbial species derived from a healthy microbiota
can potentially serve as standardized treatment, or
‘‘bacteriotherapy’’ [61]. The development of bacter-
iotherapy will require multiple complementary
approaches, including high-throughput bacterial cultur-
ing (or ‘‘culturomics’’ [62,63]) and functional charac-
terization of the human microbiota (e.g. pathway analyses
of the microbiome, metatranscriptomics or metabolo-
mics). Finally, mechanistic experiments in gnotobiotic
animal models can inform us on how specific commensals
influence colonization resistance and potentially be
utilized as a microbiota-based therapeutic.Current Opinion in Microbiology 2014, 17:67–74
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